ADAM9 antibody from Biorbyt

Yes, the ADAM9 antibody has been utilized in immunohistochemistry analyses to investigate the expression of ADAM9 in prostate cancer tissues. A study demonstrated that ADAM9 is a potential target of N-α-acetyltransferase 10 protein, which contributes to the invasive ability of androgen-independent prostate cancer cells, indicating its relevance in cancer research (lin2020).

The recommended dilution for the ADAM9 antibody in immunohistochemistry is between 1:20 and 1:200, which allows for optimal staining and visualization of the target protein in tissue samples.

Yes, the ADAM9 antibody has been cited in a scientific article that explores its role in the progression of androgen-independent prostate cancer, highlighting its potential as a biomarker and therapeutic target in clinical settings (lin2020).

The ADAM9 antibody is reactive with Homo sapiens (human), making it suitable for studies involving human tissue samples, particularly in the context of cancer research.